IMB-808

• Description :

  IMB-808 is a potent LXRα/β dual agonist with EC50 values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1) . IMB-808 can be used as a promising agent for the prospective treatment of atherosclerosis research[1].

• UNSPSC :

  12352005

• Target :

  LXR

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/imb-808.html

• Concentration :

  10mM

• Purity :

  99.85

• Solubility :

  DMSO : 250 mg/mL (ultrasonic)

• Smiles :

  O=C(N(CC(NC1=CC=C(C(F)=C1F)F)=O)C)C2=CC=C3OCCOC3=C2

• Molecular Formula :

  C18H15F3N2O4

• Molecular Weight :

  380.32

• References & Citations :

  [1]Duo Lu, et al. Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics. Mol Pharmacol. 2017 Apr;91 (4) :264-276.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [870768-70-0]